ARTICLE | Clinical News
Vical begins two Allovectin Phase II trials
February 8, 2001 8:00 AM UTC
VICL began two Phase II trials of its Allovectin lipid complexed gene therapy to stimulate immune responses against cancers. The first trial will study the reduction in tumor size prior to surgery sti...